Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 9, 2016Neuro-OncologyOpen Access

Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models

View Full Paper
Ask AI
Bookmark
Share

Authors

YPYuji PiaoThe University of Texas MD Anderson Cancer CenterSPSoon Young ParkKangwon National UniversityVHVerlene HenryThe University of Texas MD Anderson Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Piao et al. (2016) studied this question.

synapsesocial.com/papers/6aa01b14b709eacd8e71ea73https://doi.org/10.1093/neuonc/now030
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comprehensive genomic characterization defines human glioblastoma genes and core pathways2008 · 7,912 citations
  2. 2Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes2014 · 81 citations
  3. 3Bevacizumab for recurrent malignant gliomas2008 · 804 citations
  4. 4Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade2014 · 247 citations
  5. 5Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype2012 · 226 citations